Bilayer Therapeutics seeks to develop bile acids as first-in-class therapies to treat several diseases of the colon using an incretin-based mechanism of action and a unique and proprietary colonic delivery technology developed in Bob Langer’s lab at MIT. BL-050, an orally available therapy for metabolic disorders such as obesity and diabetes, acts through increasing native levels of GLP-1, GLP-2, PYY, glucagon, neurotensin, OXM, and CCK. BL-010, also orally available, acts on the receptor TGR5 and has the potential to treat several types of chronic constipation. There are additional product candidates.